GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

Shares of GoodRx have tumbled 20% this year in spite of considerable progress toward the company's ambitious goals. Healthcare is a $4 trillion annual market, and ripe for technology disruption.

GoodRx: The Growth Runway Is Long

Slowing user growth and the long shadow of a competitor dampened enthusiasm for the stock.

Why Shares of GoodRx Fell 10.7% in the First Half of 2021

Academy Sports and Outdoors

Blink Charging

Carver Bancorp

GEO Group

MicroStrategy Incorporated

Ocugen, Inc.

Root

SmileDirectClub

We're taking a look at some of the lesser-known short-squeeze stocks popular with retail investors that should be on your radar. The post 9 Lesser-Known Short-Squeeze Stocks Popular With Retail Investors appeared first on InvestorPlace.

9 Lesser-Known Short-Squeeze Stocks Popular With Retail Investors

DoorDash

"We're focused on trying to serve not just American consumers, but organizations [and] employers" in getting affordable prescriptions, CEO Doug Hirsch said.

GoodRx to assist gig workers in pharmaceutical drug discounting deal with DoorDash

 Clene Nanomedicine

iRobot

Tanger Factory Outlet Centers

Sequential Brands Group

Upstart Holdings

These shares are among the stocks with the most short sell positions The post 7 Short-Squeeze Stocks To Buy In July For Contrarian Investors appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn't matter if you have $500 in savings or $5 million.

7 Short-Squeeze Stocks To Buy In July For Contrarian Investors

Healthcare savings resource GoodRx Holdings Inc (NASDAQ: GDRX) collaborated with online food ordering and delivery platform DoorDash Inc (NYSE: DASH) to provide its network of drivers or "Dashers" with discounted access to the GoodRx Gold subscription savings program. Dashers across the country can now sign up for GoodRx Gold at an exclusive rate to access prescription savings of up to 90% on over 1,000 drugs, discounts for online doctor visits, and free mail delivery for prescriptions.

GoodRx, DoorDash Partner To Offer US Dashers With Subsidized Healthcare Facilities

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx, Inc. (NASDAQ: GDRX), America's leading resource for healthcare savings, today announced a partnership with online food ordering and delivery platform DoorDash (NYSE: DASH) to provide its network of drivers, also known as “Dashers,” with discounted access to the GoodRx Gold subscription savings program. Dashers across the country can now sign up for GoodRx Gold at an exclusive rate to access prescription savings of up to 90% on over 1,000 drugs, dis

GoodRx and DoorDash Partner to Provide Dashers Nationwide with Access to GoodRx Gold

Clover Health Investments

Arcimoto

Gogo

Ontrak

Workhorse Group

We're taking a look at the top 10 short-squeeze stocks for Tuesday with the companies that have the highest short interest. The post Short-Squeeze Stocks: Today's Top 10 Stocks With High Short Interest appeared first on InvestorPlace.

Short-Squeeze Stocks: Today's Top 10 Stocks With High Short Interest

How Will GoodRx Fare Against Competition?

With Prices Going Up, Consumers Will Flock to This Healthcare Tech Specialist

Skillz

They're beaten down. Short-sellers have piled on.

3 Great Candidates to Be the Summer's Hottest Meme Stocks

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx, Inc. (NASDAQ: GDRX), America's leading resource for healthcare savings, just released a new report that discusses the effect the company has had on the American healthcare system by helping patients afford their medications. The paper, The GoodRx Effect, discusses the ways in which GoodRx has improved social welfare by helping people access affordable healthcare: Helped Americans, with or without insurance, save on their prescription medications: I

The GoodRx Effect: How GoodRx is Changing the Economics of Healthcare

The metrics for this digital healthcare platform are headed higher for the right reasons.

Move Over, AMC: Here's a Short Squeeze Candidate With as Much Cash and a Brighter Future

You're probably paying too much for your drugs. Fortunately, there's some help on the way.

Is GoodRx the Prescription for Your Portfolio?

GoodRx has been one of the victims of the fear, uncertainty and doubt currently being propagated in the digital healthcare realm. According to the market presently, there's something of a mutually-assured destruction agreement among players such as GoodRx, Teladoc, Hims & Hers Health, and Amazon.

GoodRx: The Good Doctor Has Come To Deliver Market-Beating Returns

Accolade

American Well Corporation

Teladoc

SOC Telemed

To make the most of the booming telehealth industry, players are coming up with IPOs and resorting to mergers and acquisitions.

Booming Telehealth Market Lures More IPOs and M&A Deals

GoodRx has been hit hard along with large tech stocks, along with other worries about Amazon.

GoodRx: A Battered Stock With Tremendous Upside

This consumer healthcare platform went public last fall and is looking to shake up a big part of the healthcare industry.

Is Now the Time to Buy This Pharma Industry Disruptor?

The market is wondering what to make of GoodRx after a mixed earnings report last week. Q1 revenue was up 20 percent, rising to $160.4 million from $133.4 million a year earlier.

GoodRx Picks Its Battles With Amazon And Healthcare Costs

The shares of GoodRx Holdings Inc (NASDAQ: GDRX) have received a price target decrease from $56 to $50 by RBC Capital. These are the details.

GoodRx (GDRX) Stock: $50 Target By RBC Capital

"We're transitioning from the Covid crisis into the other health-care crisis" of affordability, GoodRx co-CEO Doug Hirsch told CNBC.

GoodRx co-CEO touts recent acquisitions, says its business is 'rock solid' and only getting better

GoodRx Holdings, Inc. (GDRX) Q1 2021 Results - Earnings Call Transcript

Discount drug broker GoodRx is acquiring its competitor RxSaver, which is owned by marketing firm Vericast, in a $50 million deal, Bloomberg reported, citing sources. Controlled by billionaire investor Ronald Perelman, who also controls Vericast, RxSaver was sold off to GoodRx last month, investors were told on a private call on Thursday (May 13), the […]

GoodRx To Acquire RxSaver In $50 Million Deal

Shares of GoodRX Holdings Inc. fell more than 5% in the extended session Thursday after the health-care company reported first-quarter sales slightly below Wall Street expectations and met the forecast for adjusted profit. GoodRx said it earned $1.7 million, breaking even on a per-share basis, in the quarter, compared with $27.3 million, or 8 cents a share, in the year-ago quarter.

GoodRx stock heads lower after mixed Q1 results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings Inc. (Nasdaq: GDRX), America's leading resource for healthcare savings, has released its first quarter 2021 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com. GoodRx management will host a conference call and webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company's business outlook. First Quarter 2021 R

News for GoodRx Holdings Stock (GDRX)